Phibro Animal Health (PAHC)
(Delayed Data from NSDQ)
$13.61 USD
+0.47 (3.58%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $13.60 -0.01 (-0.07%) 4:32 PM ET
1-Strong Buy of 5 1
A Value B Growth D Momentum B VGM
Income Statements
Fiscal Year end for Phibro Animal Health Corporation falls in the month of June .
All items in Millions except EPS data.
6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 | |
---|---|---|---|---|---|
Sales | 978 | 942 | 833 | 800 | 828 |
Cost Of Goods | 680 | 657 | 562 | 543 | 563 |
Gross Profit | 298 | 285 | 271 | 257 | 265 |
Selling & Adminstrative & Depr. & Amort Expenses | 226 | 206 | 197 | 188 | 181 |
Income After Depreciation & Amortization | 72 | 79 | 75 | 69 | 83 |
Non-Operating Income | -2 | 5 | 4 | -1 | 0 |
Interest Expense | 15 | 12 | 13 | 13 | 12 |
Pretax Income | 54 | 72 | 66 | 56 | 72 |
Income Taxes | 21 | 23 | 12 | 22 | 17 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 33 | 49 | 54 | 34 | 55 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 33 | 49 | 54 | 34 | 55 |
Depreciation Footnote | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 107 | 112 | 108 | 102 | 112 |
Depreciation & Amortization (Cash Flow) | 35 | 33 | 33 | 33 | 28 |
Income After Depreciation & Amortization | 72 | 79 | 75 | 69 | 83 |
Earnings Per Share Data | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Average Shares | 40.50 | 40.50 | 40.50 | 40.50 | 40.50 |
Diluted EPS Before Non-Recurring Items | 1.21 | 1.31 | 1.24 | 1.08 | 1.53 |
Diluted Net EPS (GAAP) | 0.81 | 1.21 | 1.34 | 0.83 | 1.35 |
Fiscal Year end for Phibro Animal Health Corporation falls in the month of June .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 249.94 | 231.35 | 255.05 | 245.67 |
Cost Of Goods | NA | 171.33 | 163.62 | 178.38 | 170.13 |
Gross Profit | NA | 78.62 | 67.73 | 76.67 | 75.54 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 62.92 | 68.45 | 52.90 | 56.99 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 15.70 | -0.72 | 23.77 | 18.55 |
Non-Operating Income | NA | -7.48 | -6.69 | 2.17 | 0.42 |
Interest Expense | NA | 4.66 | 4.56 | 4.50 | 3.87 |
Pretax Income | NA | 3.57 | -11.98 | 21.44 | 15.10 |
Income Taxes | NA | 2.29 | -3.96 | 9.94 | 5.06 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 1.27 | -8.02 | 11.50 | 10.04 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 1.27 | -8.02 | 11.50 | 10.04 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 40.50 | 40.50 | 40.50 | 40.50 |
Diluted EPS Before Non-Recurring Items | NA | 0.33 | 0.14 | 0.38 | 0.29 |
Diluted Net EPS (GAAP) | NA | 0.03 | -0.20 | 0.28 | 0.25 |